ST天圣(002872) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥135,352,879.35, a decrease of 59.48% compared to ¥334,030,966.92 in the same period last year[2] - The net profit attributable to shareholders was a loss of ¥15,756,573.03, an improvement of 37.71% from a loss of ¥25,296,030.22 year-on-year[2] - Basic and diluted earnings per share improved by 37.74%, both standing at -¥0.0495 compared to -¥0.0795 in the previous year[2] - The company reported a significant decrease in sales expenses to ¥57,312,574.16, down from ¥90,266,812.17 in the previous period, reflecting cost-cutting measures[19] - The company recorded a total comprehensive loss of -¥16,107,018.96, compared to -¥25,263,753.07 in the previous period[21] Cash Flow - The net cash flow from operating activities increased by 130.70%, reaching ¥8,970,094.74, compared to a negative cash flow of ¥29,219,215.98 in the previous year[2] - Cash flow from operating activities shows a net inflow of ¥8,970,094.74, compared to a net outflow of -¥29,219,215.98 in the previous period[24] - The net cash flow from financing activities was 12,815,643.92, compared to a negative cash flow of 8,139,738.16 in the previous period[25] - The net increase in cash and cash equivalents was -69,731,878.22, compared to -14,960,165.71 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,099,191,049.63, a slight decrease of 0.67% from ¥3,120,025,480.00 at the end of the previous year[2] - The company's current assets totaled CNY 905,832,895.16, slightly down from CNY 920,206,135.30 at the beginning of the year, indicating a decrease of approximately 1.5%[16] - Total liabilities decreased to CNY 836,061,269.02 from CNY 840,788,050.92, a slight decline of around 0.3%[17] - The company's equity attributable to shareholders decreased to CNY 2,257,674,459.83 from CNY 2,273,431,662.37, a decrease of approximately 0.7%[18] Investments and Receivables - The increase in other receivables by 136.50% was primarily due to loans made to Chongqing Yichang Changsheng Pharmaceutical Co., Ltd[5] - The company reported a significant increase in other receivables, which rose to CNY 188,023,380.33 from CNY 79,502,613.98, indicating an increase of approximately 135%[16] - Cash inflow from investment activities totals ¥130,424,863.54, an increase from ¥71,419,320.73 in the previous period[24] - Cash outflow from investment activities is ¥221,942,480.42, significantly higher than ¥49,020,532.30 in the previous period[24] Legal and Compliance - The company is currently involved in a legal case regarding bribery, with a fine of ¥3.8 million imposed, and the final judgment remains uncertain[10] Research and Development - The company has increased R&D expenses to ¥7,291,377.71, up from ¥6,091,352.39 in the previous period, indicating a focus on innovation[19] Miscellaneous - The company disposed of a piece of land, resulting in a non-operating income of ¥6,880,379.69[7] - The first quarter report was not audited[26]